Barclays raises Eli Lilly stock price target on strong tirzepatide sales

Eli Lilly reported Q1 2026 EPS of $8.55 versus $6.97 expected and revenue of $19.8B versus $17.6B expected, then raised full-year 2026 guidance to $82B-$85B revenue and $35.50-$37.00 EPS. Barclays increased its price target to $1,400 from $1,350 while maintaining Overweight, citing strong Mounjaro and Zepbound performance, though it trimmed Foundayo estimates to about $1B for FY2026. The update is constructive for Lilly and supportive for GLP-1 peers, but mixed on launch execution for Foundayo.

Analysis

The real signal is not that LLY is beating; it is that GLP-1 demand is still being monetized at full retail economics outside the US, which implies the category is not yet price-elastic in the way bears expected. That matters for the whole obesity stack because it raises the ceiling on both duration and margin durability: if consumers keep paying cash abroad, payer pushback in the US becomes a deferral risk rather than an immediate demand destroyer. The second-order winner is not just LLY, but any supplier exposed to sustained volume growth in peptides, fill/finish, and cold-chain logistics; any named or unnamed capacity bottleneck becomes a pricing lever rather than a growth constraint.

The softer point in the note is that the launch cadence looks less like a single-product story and more like a portfolio sequencing problem. If early oral adoption is good but not explosive, the market may be overestimating how quickly new formulations offset the eventual slowing of injectable share gains; that creates a near-term multiple ceiling if investors model a straight-line ramp. On the other hand, weaker IQVIA capture versus street expectations is a reminder that channel checks can lag patient-level economics, so the better read is actual refill persistence and gross-to-net behavior over the next 1-2 quarters, not week-three script counts.

NVO is the cleanest second-order loser: if LLY keeps taking share internationally and proving willingness-to-pay, Novo’s response likely has to be defensive on pricing, access, or formulation timing, which can compress its mix even if unit demand remains intact. IQV is more of a near-term data-quality casualty than a fundamental loser; if the market stops trusting third-party prescription reads, service providers tied to these datasets could see lower signaling value. Barclays itself is interesting as a sentiment catalyst, but the bigger risk is that consensus extrapolates peak enthusiasm into the back half of the year, right before growth normalizes as obesity becomes the dominant driver rather than competitive share gain.

Key Decisions for Investors

• Stay long LLY for 1-3 months, but finance part of the exposure with upside calls rather than outright stock; the setup supports continued estimate revisions, but valuation will be sensitive to any sign that growth is normalizing faster than expected.
• Short NVO vs long LLY as a relative-value pair over the next 4-8 weeks; the trade benefits if international share gains and product launch momentum remain asymmetric, with downside if LLY’s growth merely stabilizes rather than accelerates.
• Fade IQV on any rally into the next quarterly check-in; if the market begins to question prescription tracking as a leading indicator, the stock can underperform on data credibility rather than fundamentals.
• For higher-conviction risk capital, buy a 2-3 month LLY call spread instead of stock; this captures further multiple/estimate expansion while limiting damage if the market shifts focus to 2H26 deceleration.